Table 3 EVs as diagnostic biomarkers for CCA
From: The role of extracellular vesicles in cholangiocarcinoma
Biomarkers | AUC | Sensitivity | Specificity | Reference |
|---|---|---|---|---|
CCA vs. PSC BBO | [98] | |||
 Bile: miR-based panel | Null | 67% | 96% |  |
CCA vs. BBD | [103] | |||
 Bile: miR-30d-5p | 0.730 | 81.1 | 60.5 |  |
  miR-92a-3p | 0.652 | 65.7 | 66.7 |  |
 Serum: CA19-9 | 0.675 | 70.3 | 64.6 |  |
  CEA | 0.603 | 64.9 | 60.4 |  |
CCA vs. BBO | [99] | |||
 Bile lncRNAs: ENST00000588480.1 and ENST00000517758.1 | 0.709 | 82.9 | 58.9 |  |
 Serum: CA19-9 | 0.729 | 74.3 | 71.4 |  |
CCA: TNMs I, II vs. TNMs III, IV | [105] | |||
 Serum: HSP90B-s255 | 0.936 | 87.27 | 97.62 |  |
MCBDS vs. NMCBDS | [42] | |||
 Concentration of EVs | 1.000 | Null | Null |  |
 Serum: CA19-9 | 0.733 | Null | Null |  |
CCA vs. HC | [82] | |||
 Serum: miR-200c-3p | 0.930 | Null | Null |  |
 Serum: CA19-9 | 0.780 | Null | Null |  |
CCA vs. PSC | [104] | |||
 FIBG | 0.796 | Null | Null |  |
 A1AG1 | 0.794 | Null | Null |  |
 S10A8 | 0.759 | Null | Null |  |
 Serum: CA19-9 | 0.819 | Null | Null |  |
CCA vs. HC | ||||
 AMPN | 0.878 | Null | Null |  |
 VNN1 | 0.876 | Null | Null |  |
 PIGR | 0.844 | Null | Null |  |
 Serum: CA19-9 | 0.907 | Null | Null |  |